{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:56Z","timestamp":1788866936103,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CFTR gene, leading to impaired chloride transport, thickened mucus, and multiorgan dysfunction. Among its complications, cystic fibrosis-related diabetes (CFRD) is a major concern, characterized by progressive b-cell dysfunction and insulin deficiency. The advent of CFTR modulators, including ivacaftor, lumacaftor\/ivacaftor, and elexacaftor\/tezacaftor\/ivacaftor (ETI), has revolutionized CF management by improving pulmonary function, nutritional status, and overall survival. However, their effects on glucose metabolism remain under investigation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review (systematic review registration: PROSPERO 2025 CRD420251021499) analyzes recent evidence on the impact of CFTR modulators on CFRD in children and young adults. Results: Ivacaftor demonstrates potential benefits in glucose regulation, enhancing insulin secretion and glucagon control, particularly in patients with gating mutations. Conversely, lumacaftor\/ivacaftor exhibits inconsistent effects, with some studies indicating glucose tolerance improvements while others report insulin sensitivity decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>ETI therapy shows modest but generally positive effects on glycemic control, with reductions in HbA1c and fasting glucose, though without significant changes in insulin secretion. While CFTR modulators improve systemic health, their role in directly preventing or reversing CFRD remains unclear. Further longitudinal studies are needed to optimize therapeutic strategies and elucidate the long-term metabolic effects of CFTR modulation in CF patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD420251021499.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1623654","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:38Z","timestamp":1754453558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Paola","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Granberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria Pia","family":"Casolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lassandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Delvecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Linguiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.125","article-title":"Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research","volume":"16","author":"Ioannou","year":"2014","journal-title":"Genet Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/cells10112844","article-title":"CFTR protein: not just a chloride channel","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"098","DOI":"10.23937\/2378-3516\/1410098668","article-title":"A comparison between two pathophysiologically different yet microbiologically similar lung diseases: cystic fibrosis and chronic obstructive pulmonary disease","volume":"5","author":"Fenker","year":"2018","journal-title":"Int J Respir Pulm Med"},{"key":"B4","article-title":"Fibrosis qu\u00edstica: epidemiolog\u00eda, cl\u00ednica, diagn\u00f3stico y tratamiento","volume":"161","author":"Diab C\u00e1ceres","year":"2023","journal-title":"Med Cl\u00ednica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/srin.2002.31690","article-title":"Pulmonary infections in patients with cystic fibrosis","volume":"17","author":"Rajan","year":"2002","journal-title":"Semin Respir Infect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD012619","DOI":"10.1002\/14651858.CD012619.pub2","article-title":"Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis","volume":"12","author":"Carroll","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322204","article-title":"Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens","volume":"332","author":"Chill\u00f3n","year":"1995","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.11122","article-title":"Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy","volume":"39","author":"McDonald","year":"2024","journal-title":"Nutr Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0168-8227(99)00058-3","article-title":"Diagnosis, screening and management of cystic fibrosis related diabetes mellitus","volume":"45","author":"Moran","year":"1999","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32833a780d","article-title":"Recent trends in cystic fibrosis-related diabetes","volume":"17","author":"Nathan","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: An immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00718598","article-title":"Cystic fibrosis associated islet changes may provide a basis for diabetes: An immunocytochemical and morphometrical study","volume":"414","author":"L\u00f6hr","year":"1989","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490053","article-title":"Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia","volume":"149","author":"Lombardo","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00471.2005","article-title":"Influence of TNF-\u03b1 and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans","volume":"291","author":"Krogh-Madsen","year":"2006","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.07.041","article-title":"Advances in muscle health and nutrition: A toolkit for healthcare professionals","volume":"41","author":"Prado","year":"2022","journal-title":"Clin Nutr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.01.010","article-title":"Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin","volume":"18","author":"Sun","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis\u2013related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0644","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues","volume":"172","author":"Barrio","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001259","article-title":"Diabetes and prediabetes in children with cystic fibrosis","volume":"35","author":"Schiaffini","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2021.09.002","article-title":"A systematic Cochrane Review of the timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis","volume":"40","author":"Ng","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46060327","article-title":"Positive effects of physical activity on insulin signaling","volume":"46","author":"Ma\u0142kowska","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: A systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","article-title":"Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review","volume":"22","author":"Ramsey","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/life14101309","article-title":"One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on hbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: A retrospective observational study","volume":"14","author":"Bassi","year":"2024","journal-title":"Life"},{"key":"B32","doi-asserted-by":"publisher","first-page":"dgae857","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","author":"Chan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor\u2013ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation \u2013 The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study: Insulin secretion following CFTR correction","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms25063384","article-title":"Functional consequences of CFTR interactions in cystic fibrosis","volume":"25","author":"Ramananda","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1623654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:39Z","timestamp":1754453559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1623654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":44,"alternative-id":["10.3389\/fendo.2025.1623654"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1623654","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1623654"}}